JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S9

Molecular Genetics in Strategies for Opioid Addiction Management

Intiser Dhahawi Ialdhafeeri[1], Abdulrazaq M. Alenazi[2], Safanah Mohammed Al-Sagheer[3], Faten Ali Muslim AlBalawi[4], karmah Ibrahim Dasan Alenazi[5], Karima Zaal AlAnzi[6], Mishaal Nashi Dhaif Allah Al-Mutairi[7], Ashwag Hassn Masslouf[8], Manal Sahel Mosallam[9], Ahmed Mohammed Ali Al-Qarni[10], Abdul Aziz Hamoud Al-Mutair[11], Salman Ayed Alharbi[12]

1. Lab Technician at Al-Falah, Riyadh, KSA
2. Lab Specialist, Eradh Complex, Riyadh, KSA
3. Laboratory Technician, Al-Falah Health Center, Riyadh, KSA
4. Laboratory Technician, Tabuk Maternity And Children's Hospital, Riyadh, KSA
5. Technician Laboratory, Mch, Tabuk, KSA
6. Laboratory In East Al-Muhammadiyah, Hafar Al-Batin, KSA
7. Laboratory Technician, Al-Yarmouk Health Center, Al-Majmaah, KSA
8. Technician Laboratory, Original General Laboratory, Riyadh, KSA
9. Medical Laboratory, Regional Laboratory In Riyadh, , KSA
10. Laboratory Technician, Quality Management Asir Cluster, Bisha, KSA
11. Laboratory Technician, Al-Iman General Hospital , Riyadh, KSA
12. Medical Laboratory Technician, Al-Bukayriyah General Hospital, Qassim, KSA

ABSTRACT

The persistent issue of drug addiction has significantly influenced societal trends throughout history, particularly evident in events like the Opium Wars and the ongoing opioid crisis in the United States, which results in over 50,000 overdose deaths each year and imposes economic costs exceeding $500 billion annually. This research seeks to shed light on modern approaches to treating opioid use disorder (OUD) against the backdrop of limited treatment access for more than 2.6 million diagnosed individuals. We evaluate existing pharmacological treatments, including full agonists such as methadone, partial agonists like buprenorphine, and antagonist options like naltrexone, while examining their effectiveness and challenges in long-term addiction

recovery. Additionally, we investigate the impact of pharmacogenetic testing and epigenetic changes in refining OUD treatment, emphasizing the role of individual genetic factors in addiction behavior. Our results highlight the urgent need for a comprehensive strategy to treat OUD, integrating new methods that connect scientific findings with practical application to tackle the complexities of addiction. We recommend improved training for clinicians, efforts to diminish stigma surrounding medication, and the adoption of innovative treatment strategies as vital elements in addressing the current opioid crisis and averting future epidemics.

1. Introduction

The challenge of drug abuse has frequently marked significant epochs in human history. A century and three-quarters ago, with the release of the inaugural issue of what would later be known as the American Journal of Psychiatry, the Opium Wars overshadowed life across Asia. Initially brought into China for medicinal use, opium quickly shifted to recreational consumption and widespread addiction, causing devastation throughout various societal levels. As Chinese emperors sought to curb this epidemic, Western powers engaged in conflicts to boost opium imports and taxes. Another heroin crisis emerged, particularly impacting urban areas in the United States during the 1970s, with American veterans of the Vietnam War being a major driving force behind the establishment of the Drug Enforcement Administration (DEA) in 1973 [1]. Today, a new wave of opioid addiction has affected every demographic group in the U.S., creating a significant healthcare and societal burden of epidemic scale, with economic repercussions exceeding $500 billion annually.

The opioid crisis affecting the nation has largely arisen from a skewed and inaccurate perception of addiction vulnerability, exacerbated by a significant over-prescription of opioid painkillers, which annually surpassed the clinical requirements of the entire adult population in the USA [2]. This widespread availability of strong opioids across various socioeconomic groups has driven many toward heroin; about 80% of new heroin users initially misused prescription opioid analgesics. Additionally, the illegal and more affordable alternatives to prescription drugs, such as fentanyl, gained traction as federal regulations limited access to legal prescriptions. The repercussions have been alarming, with over 50,000 overdose fatalities each year [3], a figure projected to persist without significant intervention. The overwhelming impact of the opioid crisis has resulted in severe medical challenges, illustrated by an astounding 3000% increase in healthcare services required for patients dealing with opioid misuse and dependence. This is reflected in the rise from approximately 217,000 patients receiving medical care in 2007 to nearly 7 million by 2014 [4].

Despite the urgent need for therapeutic interventions to address the opioid crisis, a majority of the over 2.6 million individuals diagnosed with an opioid use disorder (OUD) receive limited treatment for their addiction. The primary pharmacotherapies for OUDs are opioid substitution medications, which ironically face significant stigma and stringent governmental regulations due to their potential for abuse and risk of diversion to the illicit market [5]. Furthermore, these treatments necessitate intensive

clinical monitoring, contributing to a substantial healthcare burden. Consequently, coupled with a shortage of clinicians qualified to recognize and treat substance use disorders, the current treatment system has struggled to adequately address the vast number of individuals requiring care during this epidemic. We propose that a multifaceted strategy, incorporating a wide array of treatment options grounded in scientific principles, is essential not only to tackle the present crisis but also to avert future outbreaks [6].

Objectives:

We aimed in this study to:

1. Identify the current Strategies of Opioid treatments
2. Assess the role of pharmacogenetic testing in optimizing medication prescriptions for individuals with opioid use disorder.
3. Examine epigenetic modifications linked to opioid exposure and how they influence addiction behaviors.

Addiction is recognized as a chronic disorder of the brain that necessitates prolonged treatment. Alarmingly, advertisements promoting costly addiction "cures" that claim to resolve issues after just 30 days in a spa-like residential program with group therapy demonstrate a profound misunderstanding of the extensive clinical research available. These abstinence-only residential treatment programs, despite their claims of offering a "cure," are associated with notably high relapse rates soon after individuals "graduate" or are discharged. In contrast, medication-assisted treatment (MAT) has been shown to yield the most favorable long-term outcomes, particularly for opioid use disorder, with several medication options currently available [7].

The full agonist approach is represented by methadone, a treatment that originated in the 1960s when it became clear that individuals suffering from opioid addiction could achieve stabilization with a single daily dose of methadone, leading to reduced cravings and drug-seeking behavior. Over more than five decades, extensive research has demonstrated that patients receiving methadone, especially when combined with counseling, can function effectively in educational and professional environments while enjoying a high quality of life. Although tolerance develops to all opioid agonists, including methadone, this tolerance does not continuously escalate, allowing for the medication to be maintained at a stable dose over many years. However, challenges may arise when the medication is stopped, as detoxification can be difficult and may take several months [8].

The partial agonist approach is illustrated by buprenorphine, a medication that has a strong affinity for the mu opioid receptor (MOR) but also has a built-in limit or "ceiling" on its maximum opioid effects. Like methadone, buprenorphine effectively reduces cravings and drug-seeking behaviors; however, due to its capped effect, patients with severe opioid dependence may not be ideal candidates for a direct switch to buprenorphine. In the United States, a frequently prescribed combination therapy includes buprenorphine and naloxone, known as Suboxone. When administered via injection rather than the usual oral or sublingual methods, naloxone helps to reduce the rewarding effects associated with MOR activation, thus discouraging potential misuse [9].

A recent development in treatment is the introduction of various extended-release injectable formulations. One such formulation, designed to release buprenorphine gradually over a 30-day period, is expected to be marketed starting in 2018. Additionally, other formulations that can last up to six months are currently under evaluation by the FDA.

The antagonist approach is represented by naltrexone, which received FDA approval for its oral formulation in 1985. Naltrexone binds to opioid receptors, preventing agonist drugs like heroin or methadone from attaching to these receptors. As a pure antagonist, it does not produce euphoria or a sense of reward. The oral formulation requires daily administration or usage three times a week; however, patients may relapse simply by stopping the medication for 48 hours. As a result, the oral version of naltrexone has demonstrated very limited effectiveness. Recently, an extended-release formulation of naltrexone has been introduced [10]. This modified version aids in preventing relapse to opioid addiction for a duration of 30 days. Many patients prefer the convenience of a monthly injection over daily medication. In a clinical trial conducted in 2016 involving volunteer patients on probation, those assigned to six months of extended-release naltrexone showed significantly more drug-negative urine tests and lower relapse rates compared to those receiving standard community treatments [11]. Despite these advantages, antagonist treatments have not yet gained widespread acceptance. Integrating them into standard opioid agonist treatment protocols poses challenges, as detoxification must occur prior to the administration of an antagonist. The initial detoxification typically takes place in a residential treatment setting, creating a critical clinical opportunity to initiate antagonist therapy before individuals leave the supportive environment.

The term "epigenetics" is now utilized with both traditional and recently updated definitions. Classical definitions of "epigenetic" focus on influences that are not encoded in the primary DNA sequence but are still inherited, describing it as "... a change in the state of expression of a gene that does not involve a mutation, but that is nevertheless inherited in the absence of the signal (or event) that initiated the change" [12]. In contrast, more recent definitions of "epigenetic" emphasize gene regulatory mechanisms that do not alter the primary DNA sequence while placing less emphasis on documenting heritability.

This review primarily concentrates on heritable epigenetic factors. A notable example of a classical heritable epigenetic influence is imprinting, which conveys information from parents to offspring through mechanisms such as DNA methylation or histone acetylation. These processes maintain the primary DNA sequence while significantly altering the function of specific genes. For instance, DNA methylation at CpG sites within gene promoter regions can greatly influence gene transcription. The process of methylation during the development of maternal oocytes (or paternal sperm) is crucial, leading to observable patterns of gender-specific inheritance that underscore this particular subset of heritable ep igenetic influence [13]. However, the quality of existing family datasets related to addiction is relatively low, which restricts their utility in drawing strong conclusions about parent-of-origin effects. To date, there is no segregation data that supports significant parent-of-origin effects on substance dependence. While it is evident that nonheritable "epigenetic" factors play important roles in the biology of addiction, convincing evidence of strong effects from overall heritable "epigenetic" influences, as traditionally defined, remains lacking. Nonetheless, it is essential to remain attentive to such influences as we investigate the impacts of variants in specific genes [14].

The genetic foundations of substance use disorders are frequently examined. Traditional genetic methodologies, including twin, family, and adoption studies, indicate that there are substantial genetic influences on drug addiction. Heritability refers to the proportion of observed differences in a phenotypic trait among individuals within a population that can be attributed to genetic differences, with the heritability of addiction estimated to be between 0.4 and 0.6 [15]. Recent advancements in computer technology have facilitated molecular genetic approaches, enabling linkage studies, genetic association studies, and genome-wide association studies to identify and locate associated genes. Numerous studies have now been conducted on addiction behaviors utilizing molecular methodologies [16]. Traditional genetic approaches have established that addiction is heritable, while molecular genetic approaches suggest that specific addiction-related behaviors correlate with specific genes.

Genetic epidemiology is a rapidly evolving field that provides valuable insights into the complexities of substance use disorders [17]. By integrating findings from both traditional genetic research and contemporary molecular genetic studies, researchers can uncover critical information regarding the genetic underpinnings of various addiction-related disorders. This section aims to review the latest genetic research concerning disorders associated with substances such as tobacco, alcohol, and opiates. Furthermore, the subsequent section will explore potential genetic connections between opioid addiction and specific behavioral patterns. In their comprehensive review, Kreek et al. proposed a three-domain model to understand the interplay between genetics, diverse environmental influences, and drug-induced effects in the context of addiction [18]. Historical investigations into the genetic aspects of addiction

can be traced back to 1960, when Kaij et al. conducted pioneering research on alcoholism in twins, laying the groundwork for subsequent studies. In 1966, Partanen et al. followed up with a similar twin study that examined the correlations between cognitive factors such as intelligence and personality traits in relation to alcohol consumption. These early investigations were significant as they suggested a heritable component to specific addictions, indicating that genetics play a critical role in the predisposition to substance use disorders [19]. Further reinforcing the genetic link to alcohol abuse, Cloninger et al. conducted an adoption study that demonstrated a notable resemblance in alcohol-related behaviors among adopted individuals and their biological relatives, as opposed to their adoptive families. The findings from this research provided a classical method for distinguishing the impacts of genetic factors from environmental influences [20]. In another significant study conducted in 1988, Merikangas et al. reported that relatives of individuals suffering from drug disorders were eight times more likely to experience similar issues themselves, particularly for those addicted to the same substance, highlighting the familial aggregation of such disorders [21]. In an influential twin study, Tsuang posited that both genetic predispositions and environmental factors significantly contribute to an individual's risk for drug abuse. Tsuang's research further revealed that commonly abused substances—namely, opiates, marijuana, sedatives, psychedelics, and stimulants—exhibited an overall genetic variance estimated between 0.3 and 0.5. Among these substances, heroin was noted to possess the highest overall genetic variance at 0.54, along with a shared genetic variance of 0.2 with other substances. Interestingly, while many drugs demonstrated low variance concerning specific genetic influences, heroin stood out with a unique specific genetic variance of 0.4, suggesting that particular genetic factors may uniquely affect opioid abuse. In a landmark twin study focusing on substance use disorders, Kendler and colleagues found that lifetime use of substances such as cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates exhibited a range of additive genetic variance, or heritability, ranging from 0.3 to 0.5 [22]. These foundational studies—from twin studies to adoption studies and spanning across substances from alcohol to various other drugs—offer robust evidence supporting the significant role of genetics in the development of substance use disorders. Building upon these classical genetic investigations, recent molecular genetic studies have further examined heritability in a more nuanced manner.

2. Conclusion:

In conclusion, the opioid epidemic presents an urgent and complex public health crisis that requires a multi-faceted response encompassing medical, psychological, and societal interventions. Despite significant advancements in understanding the genetic and epigenetic underpinnings of addiction, as well as the implementation of various pharmacotherapeutic strategies, a substantial treatment gap persists for those affected by opioid use disorders. Current approaches, including full agonists, partial agonists,

and antagonists, demonstrate varying levels of efficacy, highlighting the need for personalized and adaptive treatment plans tailored to individual patients. Furthermore, ongoing research into genetic susceptibility and epigenetic influences is essential to refine treatment options and inform prevention strategies. As we navigate this multifarious challenge, it is imperative to integrate science-driven methodologies with compassionate care to alleviate the profound toll of opioid addiction on individuals and society as a whole. Addressing these intertwined dimensions will be crucial in curbing the epidemic and preventing future outbreaks, ensuring that those in need receive comprehensive support and effective treatment.

References

1. Lovell J. The Opium War: Drugs, Dreams, and the Making of Modern China. The Overlook Press: 2015. [Google Scholar]
2. Fay P. The Opium War, 1840-1842: barbarians in the Celestial Empire in the early part of the nineteenth century and the war by which they forced her gates ajar. 2000 [Google Scholar] The DEA Years: 1970-1975. https://www.dea.gov/about/history.shtml. Advisers TCoE: The Underestimated Cost of the Opioid Crisis. 2017 [Google Scholar]
3. Muhuri P, Gfroerer J, Davies C. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. http://archive.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-relieveruse2013.pdf2013.
4. Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerda M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BD. Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study. Addiction. 2016;111:2021–2031. [PMC free article] [PubMed] [Google Scholar]
5. Compton WM, Jones CM, Baldwin GT. Relationship between Nonmedical PrescriptionOpioid Use and Heroin Use. N Engl J Med. 2016;374:154–163. [PubMed] [Google Scholar] Provisional Counts Of Drug Overdose Deaths, as of 8/6/2017. CDC •National Center for Health Statistics• National Vital Statistics System. 2017 [Google Scholar]
6. Ahmad F, Rossen L, Spencer M, Warner M, Sutton P. Provisional drug overdose death counts CDC/National Center for Health Statistics. 2018 [Google Scholar]
7. The Impact of the Opioid Crisis on the Healthcare System. A FAIR Health White Paper. FAIR Health; 2016. [Google Scholar]
8. McDonald RD, Tofighi B, Laska E, Goldfeld K, Bonilla W, Flannery M, Santana-Correa N, Johnson CW, Leibowitz N, Rotrosen J, Gourevitch MN, Lee JD. Extended-release naltrexone opioid treatment at jail reentry (XOR) Contemp Clin Trials. 2016;49:57–64. [PMC free article] [PubMed] [Google Scholar]
9. Ptashne M. On the use of the word 'epigenetic'. Curr Biol. 2007;17(7):R233–R236. [PubMed] [Google Scholar]

10. Tan EK. The role of common genetic risk variants in Parkinson disease. Clin Genet. 2007;72(5):387–393. [PubMed] [Google Scholar]
11. Kendler K.S., Jacobson K.C., Prescott C.A., Neale M.C. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am. J. Psychiatry. 2003;160:687–695. doi: 10.1176/appi.ajp.160.4.687. [PubMed] [CrossRef] [Google Scholar]
12. Tsuang M.T., Lyons M.J., Meyer J.M., Doyle T., Eisen S.A., Goldberg J., True W., Lin N., Toomey R., Eaves L. Co-occurrence of abuse of different drugs in men: The role of drugspecific and shared vulnerabilities. Arch. Gen. Psychiatry. 1998;55:967–972. doi: 10.1001/archpsyc.55.11.967. [PubMed] [CrossRef] [Google Scholar]
13. Xie P., Kranzler H.R., Krauthammer M., Cosgrove K.P., Oslin D., Anton R.F., Farrer L.A., Picciotto M.R., Krystal J.H., Zhao H. Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol. Psychiatry.2011;70:528–536. doi: 10.1016/j.biopsych.2011.04.017. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
14. Burton P.R., Tobin M.D., Hopper J.L. Key concepts in genetic epidemiology. Lancet. 2005;366:941–951. doi: 10.1016/S0140-6736(05)67322-9. [PubMed] [CrossRef] [Google Scholar]
15. Kreek M.J., Nielsen D.A., LaForge K.S. Genes associated with addiction: Alcoholism, opiate, and cocaine addiction. Neuromol. Med. 2004;5:85–108. doi: 10.1385/NMM:5:1:085. [PubMed] [CrossRef] [Google Scholar]
16. Kaij L., Rosenthal D. Alcoholism in twins. Studies on the etiology and sequels of abuse of alcohol. J. Nerv. Ment. Dis. 1961;133:272. doi: 10.1097/00005053-196109000-00019. [CrossRef] [Google Scholar]
17. Partanen J., Bruun K., Markkanen T. Inheritance of Drinking Behavior: A study on Intelligence, Personality, and Use of Alcohol of Adult Twins. Volume 14 Finnish Foundation for Alcohol Studies; Stockholm, Sweden: 1966. [Google Scholar]
18. Cloninger C.R., Bohman M., Sigvardsson S. Inheritance of alcohol abuse: Cross-fostering analysis of adopted men. Arch. Gen. Psychiatry. 1981;38:861–868. doi: 10.1001/archpsyc.1981.01780330019001. [PubMed] [CrossRef] [Google Scholar]
19. Merikangas K.R., Stolar M., Stevens D.E., Goulet J., Preisig M.A., Fenton B., Zhang H., O'Malley S.S., Rounsaville B.J. Familial transmission of substance use disorders. Arch. Gen. Psychiatry. 1998;55:973–979. doi: 10.1001/archpsyc.55.11.973.